Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CROWN mesalazine withdrawal trial in Crohn's disease
NL-OMON28798Phase 4Active, not recruiting
- Sponsor
- University Medical Center Utrecht
- Start
- Dec 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of Salcrozine in Crohn's disease (2 arms), sponsored by University Medical Center Utrecht. Primary endpoints: Clinical relapse during 18 months and Cost-effectiveness. Started Dec 2009; status: active, not recruiting.
02
Drugs
Salcrozine
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NL-OMON28798.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON28798.